Perspective trends of topical therapy of patients with psoriasis

Topical medications are used to treat not only limited, but also common forms of the disease. Currently prescribed external anti-inflammatory drugs have a low selectivity of action, which does not allow achieving a long-term and pronounced clinical effect without the development of undesirable pheno...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Alexander S. Zhukov, Vladislav R. Khairutdinov, Alexey V. Samtsov
Formato:	article
Lenguaje:	RU
Publicado:	State Scientific Center of Dermatovenereology and Cosmetology 2021
Materias:	psoriasis topical therapy methotrexate memory cells serine proteases Dermatology RL1-803
Acceso en línea:	https://doaj.org/article/275bf647a7b240028eead92c703a51d5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:275bf647a7b240028eead92c703a51d5
record_format	dspace
spelling	oai:doaj.org-article:275bf647a7b240028eead92c703a51d52021-12-01T22:16:30ZPerspective trends of topical therapy of patients with psoriasis0042-46092313-629410.25208/vdv1212https://doaj.org/article/275bf647a7b240028eead92c703a51d52021-04-01T00:00:00Zhttps://vestnikdv.ru/jour/article/viewFile/1212/1177https://doaj.org/toc/0042-4609https://doaj.org/toc/2313-6294Topical medications are used to treat not only limited, but also common forms of the disease. Currently prescribed external anti-inflammatory drugs have a low selectivity of action, which does not allow achieving a long-term and pronounced clinical effect without the development of undesirable phenomena. This review presents new options for the use of methotrexate in modern topical forms (AuNPs-3MPS), which make it possible to reduce the incidence of adverse events with a high efficiency of therapy. Shown is an innovative drug that blocks resident memory cells (PAP-1), which will influence the course and relapses of the disease, and possibly even lead to the cure of the patient from psoriasis. A new direction has been described inhibition of serine proteases (ER143, AAN-16) and thus inhibition of IL-36-mediated inflammation, which will allow controlling the inflammatory process in psoriasis in the early stages of its development. In addition, a number of drugs are shown whose action is based on blocking intracellular signaling pathways, which leads to inhibition of the development of the inflammatory response and resolution of psoriatic eruptions: inhibitors of Janus kinases (tofacitinib), transcription factor Stat3 (rS3-PA), secondary messenger of signals (SIS3), phosphodiesterase 7 (ASB16165) and 4 (AN-2728/crisaborol), ROR transcription factor (PF-06763809), phospholipase A2 (AVX001), hydrolases (DZ2002). The results of preclinical and initial stages of clinical trials with an assessment of the safety and tolerability of the studied substances are presented. Based on the review, the advantages and disadvantages of the proposed drugs are characterized. Topical therapy with a selective effect on the key links in the development of psoriasis will increase the effectiveness of treatment and reduce the frequency of unwanted effects.Alexander S. ZhukovVladislav R. KhairutdinovAlexey V. SamtsovState Scientific Center of Dermatovenereology and Cosmetologyarticlepsoriasistopical therapymethotrexatememory cellsserine proteasesDermatologyRL1-803RUVestnik Dermatologii i Venerologii, Vol 97, Iss 2, Pp 61-68 (2021)
institution	DOAJ
collection	DOAJ
language	RU
topic	psoriasis topical therapy methotrexate memory cells serine proteases Dermatology RL1-803
spellingShingle	psoriasis topical therapy methotrexate memory cells serine proteases Dermatology RL1-803 Alexander S. Zhukov Vladislav R. Khairutdinov Alexey V. Samtsov Perspective trends of topical therapy of patients with psoriasis
description	Topical medications are used to treat not only limited, but also common forms of the disease. Currently prescribed external anti-inflammatory drugs have a low selectivity of action, which does not allow achieving a long-term and pronounced clinical effect without the development of undesirable phenomena. This review presents new options for the use of methotrexate in modern topical forms (AuNPs-3MPS), which make it possible to reduce the incidence of adverse events with a high efficiency of therapy. Shown is an innovative drug that blocks resident memory cells (PAP-1), which will influence the course and relapses of the disease, and possibly even lead to the cure of the patient from psoriasis. A new direction has been described inhibition of serine proteases (ER143, AAN-16) and thus inhibition of IL-36-mediated inflammation, which will allow controlling the inflammatory process in psoriasis in the early stages of its development. In addition, a number of drugs are shown whose action is based on blocking intracellular signaling pathways, which leads to inhibition of the development of the inflammatory response and resolution of psoriatic eruptions: inhibitors of Janus kinases (tofacitinib), transcription factor Stat3 (rS3-PA), secondary messenger of signals (SIS3), phosphodiesterase 7 (ASB16165) and 4 (AN-2728/crisaborol), ROR transcription factor (PF-06763809), phospholipase A2 (AVX001), hydrolases (DZ2002). The results of preclinical and initial stages of clinical trials with an assessment of the safety and tolerability of the studied substances are presented. Based on the review, the advantages and disadvantages of the proposed drugs are characterized. Topical therapy with a selective effect on the key links in the development of psoriasis will increase the effectiveness of treatment and reduce the frequency of unwanted effects.
format	article
author	Alexander S. Zhukov Vladislav R. Khairutdinov Alexey V. Samtsov
author_facet	Alexander S. Zhukov Vladislav R. Khairutdinov Alexey V. Samtsov
author_sort	Alexander S. Zhukov
title	Perspective trends of topical therapy of patients with psoriasis
title_short	Perspective trends of topical therapy of patients with psoriasis
title_full	Perspective trends of topical therapy of patients with psoriasis
title_fullStr	Perspective trends of topical therapy of patients with psoriasis
title_full_unstemmed	Perspective trends of topical therapy of patients with psoriasis
title_sort	perspective trends of topical therapy of patients with psoriasis
publisher	State Scientific Center of Dermatovenereology and Cosmetology
publishDate	2021
url	https://doaj.org/article/275bf647a7b240028eead92c703a51d5
work_keys_str_mv	AT alexanderszhukov perspectivetrendsoftopicaltherapyofpatientswithpsoriasis AT vladislavrkhairutdinov perspectivetrendsoftopicaltherapyofpatientswithpsoriasis AT alexeyvsamtsov perspectivetrendsoftopicaltherapyofpatientswithpsoriasis
_version_	1718404150453075968

Perspective trends of topical therapy of patients with psoriasis

Ejemplares similares